Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01491958 · ClinicalTrials.gov registry record · Phase 2
Safety & Efficacy of Atorvastatin for Prophylaxis of Acute Graft Versus Host Disease in Patients With Hematological Malignancies HLA- Donor Hematopoietic Stem Cell Transplantation
A Phase 2 study, sponsored by Ohio State University Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
NCT01491958 is a Phase 2 study that has completed, run by Ohio State University Comprehensive Cancer Center. The registered enrollment target is 40 participants.
The verdict
NCT01491958, a Phase 2 study, has completed, sponsored by Ohio State University Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
Study Summary
Phase II trial evaluating the safety \& efficacy of Atorvastatin for prophylaxis of Acute Graft Versus Host Disease (GVHD) in patients with hematological malignances undergoing human leukocyte antigen (HLA)-Matched Related Donor Hematopoietic Stem Cell Transplant (HSCT).
Interventions
- DRUG Tacrolimus
- DRUG methotrexate
- DRUG atorvastatin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2011-12-10 |
| Est. Completion | 2016-06-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01491958
The ClinicalTrials.gov registry entry for NCT01491958 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ohio State University Comprehensive Cancer Center, which has 341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Tacrolimus is the first listed.
NCT01491958 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01491958 about?
NCT01491958 is a clinical study titled "Safety & Efficacy of Atorvastatin for Prophylaxis of Acute Graft Versus Host Disease in Patients With Hematological Malignancies HLA- Donor Hematopoietic Stem Cell Transplantation". Phase II trial evaluating the safety \& efficacy of Atorvastatin for prophylaxis of Acute Graft Versus Host Disease (GVHD) in patients with hematological malignances undergoing human leukocyte antigen (HLA)-Matched Related Donor Hematopoietic Stem Cell Transplant (HSCT).
What is the current status of trial NCT01491958?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2011-12-10. Estimated completion is 2016-06-27.
What interventions are being tested in trial NCT01491958?
The interventions under investigation include: Tacrolimus (DRUG), methotrexate (DRUG), atorvastatin (DRUG).
Who is sponsoring clinical trial NCT01491958?
This trial is sponsored by Ohio State University Comprehensive Cancer Center, which has 341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.